Huaiqihuang granules for kidney inflammation in CKD stage 3
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether Huaiqihuang granules can improve primary glomerulonephritis (a kidney inflammation) in people with chronic kidney disease at stage 3. It may help control kidney-related measures and reduce progression, compared with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with primary glomerulonephritis confirmed by a kidney biopsy
- You are age 18 to 65
- Your blood pressure can be kept at 140/90 or lower
- Your kidney function is stage 3 (eGFR between 30 and under 60)
- Your urine protein is 2.0 grams or less in 24 hours
- You can understand the study and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether Huaier granules can improve kidney disease activity in people with “idiopathic membranous nephropathy” who test positive for PLA2R antibodies and are still not in remission. Participants will also have been on standard blood-pressure/kidney-protecting treatment (called RASI) for at least 4 weeks.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This trial tests a new drug, HS-10390, to see if it can help people with IgA nephropathy. You may qualify if you have the condition, are on stable blood pressure medication, and meet certain kidney function and lab criteria.
This trial tests a new treatment called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can safely reduce protein in the urine and help protect kidney function.
This trial tests a new drug called QLS7305 in people with certain kidney diseases like IgAN, PMN, C3G, or IC-MPGN. The goal is to see if it reduces protein in the urine and is safe.
Hear when a new Renal Insufficiency, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.